Loading...

Saturday, 31 March 2012

- OZONE: MIGRANE


Migraine


Migraines are generally caused by seratonins released by red cell plateletes. Certain chemicals causes their release. A study in Italy found that 25% of migraines are also caused by the bacteria, H pylori.


Application of ozone therapy was based on the notions of a significant role of lipid peroxidation in the pathogenesis of migraine attacks. A therapy was performed in form of intravenous infusions of the ozonized physiologic solutions with ozone, concentration 1200 micrograms/l; a therapy course included 8-9 procedures.
The investigation included 68 patients: most of them had migraine without aura (64%); migraine with aura was diagnosed in 36% of cases. In the structure of aura visual disturbances and paresthesia were dominant. One patient had ophtalmoplegic migraine.
Average age of patients was 26,3 years. The women predominated over the men (71%). The frequency of migraine attack ranged from 2-3 per week to 5-6 per year. Most of the cases showed one-sided character of headache (73% of the investigated patients). In 32% of the patients paroxysms were associated with tension headache in the interictal period.
Ozone therapy was included into the complex treatment of 50 patients of the main (experimental) group.
Recommended methods of ozone therapy:
·   Intravenous drop-by-drop infusions of ozonated saline solution.
Along with neurological status, the results of treatment were evaluated on the basis of thorough examination of patients including the investigation into the cerebral neurodynamics, haemodynamics, vegetative regulation of heart rhythm, intensity of headache, anxiety, lipid peroxidation processes, antioxidant activity of blood plasma.
The results of dynamic observation have shown that the use of ozonated saline drips as a component of complex treatment increases its efficiency by 29%. The number of discharged patients with good therapeutic effect in main group (87%) was reliably higher than in control group (61%, p<0,05). The absence of non-responders among the patients received ozone therapy allows considering the latter as a reliable method of preventing resistance to the provided therapy in this contingent of patients.
Ozonated saline drips used in the interictal period ensured in 58% of the patients no migraine paroxysms within 4 to 8 months (in average 6,2 months) after their discharge from hospital. In other 19% of the patients the duration of attackless interval was limited to 3 months. However, after repeated migraine attacks, the frequency of attacks and intensity of headache were considerably less (on average 4,3+ 0,31 points according to the visual analog scale) than before the treatment.
The experience in the use of ozonated saline drips during the migraine paroxysm points out a clear correlation between the time from the beginning of headache to the point when ozone therapy was performed and its efficiency. As sooner the procedure was performed as less intensive was headache in further.
Basing on the received results it is obvious that the use of ozonated saline drips both as a component of complex treatment and as a monotherapy allows achieving a stable clinical effect in a relatively short time. The performance of repeated courses of ozone therapy with frequency 2-3 times per year allows to improve considerably the life quality of patients with migraine, significantly reduce the time of their disability.
The use of the above-mentioned methods of ozone therapy is more effective in the interictal period, but the method of ozonated saline drips can be included into the list of basic measures used for stopping migraine attack.
The efficiency of ozone therapy in the given contingent of patients was connected with the influence of the secondary products of ozone on the key pathogenetic mechanisms. The improvement of conditions for neuron's membrane function, normalization of rheological properties of blood through ozone therapy can be successfully added to immediate analgesic effect of ozonated saline drips through the interference of basic mediators of noci- and antinociceptive brain systems into the metabolism.

3 comments: